Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model - Fang, Gang; Pi, Zhipeng; An, Yiping; Cao, Xinxin; Li, Wei; Zhu, Xiangjun; Ding, Jinxi (Frontiers in Pharmacology, 2025)